Significant Ownership of COLUMN GROUP II, LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for COLUMN GROUP II, LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ James Evangelista, Attorney-in-Fact - James Evangelista, Attorney-in-Fact
- Manager location
- San Francisco, CA
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow COLUMN GROUP II, LP and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from COLUMN GROUP II, LP
Significant Ownership of COLUMN GROUP II, LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| RAPT | RAPT Therapeutics, Inc. | Common Stock, $0.0001 par value | 4.9% | $1,395,126 | 1,603,593 | Peter Svennilson | 23 Dec 2024 | ||
| ORIC | ORIC Pharmaceuticals, Inc. | Common Stock, $0.0001 par value per share | 3.7% | $48,612,534 | 3,644,118 | Peter Svennilson | 30 Sep 2025 |
Schedules 13D/G Reported by COLUMN GROUP II, LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.